QUEBEC CITY, May 27, 2011 /CNW Telbec/ - DiagnoCure, Inc. (TSX: CUR), a
life sciences company commercializing high‐value cancer diagnostic
tests and delivering laboratory services, announced today that the
Company will release its second quarter 2011 results on June 6, 2011,
at approximately 4:30 p.m. (EDT). This release will be followed by a
conference call, which will be held on June 7, 2011, at 9:00 a.m.
(EDT). The conference will begin with a brief presentation, followed by
a question-and-answer period.
The event will be webcast live through DiagnoCure's website at www.diagnocure.com, through a link on the Investors page - Presentations.
For those who wish to take part in the conference call for the Q&A
period, please dial the phone number, provide the subject «DiagnoCure
Q2 earnings announcement» and the Conference ID: 4441362. Access phone
numbers for participants from Montreal is 514-807-8791 and for other
participants the toll-free number is 1-800-732-1073.
For those unable to participate, a replay of the audio conference will
also be available on DiagnoCure's website as of June 8, 2011, also
through a link on the Investors page - Presentations.
DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering laboratory services
that increase clinician and patient confidence in making critical
treatment decisions. DiagnoCure Oncology Laboratories, a subsidiary of
DiagnoCure, Inc., launched in 2008 the PrevistageTM GCC Colorectal Cancer Staging Test, the first GCC-based molecular test
for the management of colorectal cancer. To date, two major studies
(JAMA 2009 and Ann Surg Onc. 2011) have demonstrated that the GCC
biomarker, to which DiagnoCure owns exclusive worldwide diagnostic
rights, of all the risk factors compared in the studies is the
strongest independent predictor of colorectal cancer recurrence. The
Company has a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the
development and commercialization of a second-generation prostate
cancer test using PCA3, DiagnoCure's proprietary molecular marker. This
test is available through laboratories in the U.S. and in Canada using
PCA3 analyte specific reagents (ASR) from Gen-Probe, and in Europe as
the CE-marked PROGENSA® PCA3 in vitro assay. Gen-Probe completed a 500-patient clinical study aimed at
securing FDA approval for the commercialization of the PROGENSA® PCA3
test in the U.S. and filed a PMA in September 2010. For more
information, visit www.diagnocure.com.
This release contains forward‐looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual
results to differ materially from those expected. By their very nature,
forward‐looking statements are based on expectations and hypotheses and
also involve risks and uncertainties, known and unknown, many of which
are beyond DiagnoCure's control. As a result, investors are cautioned
not to place undue reliance on these forward‐looking statements. The
forward-looking statements regarding the outcome of research and
development projects, clinical studies and future revenues are based on
management expectations. In addition, the reader is referred to the
applicable general risks and uncertainties described in DiagnoCure's
most recent Annual Information Form under the heading "Risk Factors".
DiagnoCure undertakes no obligation to publicly update or revise any
forward‐looking statements contained herein unless required by the
applicable securities laws and regulations.
SOURCE DIAGNOCURE INC.
For further information: